|Articles|June 1, 2001

FDA mandates new labels for anti-fungals

Miami - The FDA last month issued a health warning concerning two popular anti-fungal drugs used to treat onychomycosis, requiring that labels for Sporanox (Janssen Pharmaceuticals) and Lamisil (Novartis) carry stronger warnings about potential liver damage. Sporanox also must warn against potential heart disease, the administration said.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME